Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tylenol extensions

This article was originally published in The Tan Sheet

Executive Summary

Extra Strength Rapid Release Gels "have specially designed holes in the gelcap that allow the medicine to be released more quickly than before," McNeil announces. The gels are rolling out now at food, drug and mass retailers in 24-, 50- and 100-count packages with SRPs of $4.99, $6.00 and $9.99, respectively. Rapid Release will be backed by a national campaign. Tylenol Allergy Complete (acetaminophen, chlorpheniramine maleate and pseudoephedrine HCl) features the brand's Cool Burst coating to provide "an instant cooling sensation upon administration of the medicine." The 24-and 48-count packages will cost $5.99 and $8.99 when they hit shelves in March, supported by radio and an April 3 FSI drop...

You may also be interested in...



Rapid Release, Rapid Success: Tylenol Launch Spawns Generic Imitators

The recent success of Tylenol Extra Strength Rapid Release Gels has caught the attention of private labelers

Tylenol Gains On COX-2 Fallout, Drives J&J Consumer Sales

Tylenol first-quarter sales benefited from the publicity surrounding COX-2 safety issues, according to Johnson & Johnson

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel